IMWG | ISS

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

By imwgimf On June 16, 2016 · Add Comment · In IMWG Publications, Treatment Options

The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The prognosis of patients showing these abnormalities may vary with the choice of therapy. Treatment strategies have shown promise for HR cytogenetic diseases, such as proteasome inhibition in combination with lenalidomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of immunotherapy with lenalidomide or pomalidomide. Careful analysis of cytogenetic subgroups in trials comparing different treatments remains an important goal. Cross-trial comparisons may provide insight into the effect of new drugs in patients with cytogenetic […]

Combining Fluorescent In Situ Hybridization (iFISH) data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group (IMWG) collaborative project

By imwgimf On March 27, 2013 · Add Comment · In Diagnosis, Staging & Monitoring, IMWG Publications

Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma

By imwgimf On May 13, 2008 · Add Comment · In Diagnosis, Staging & Monitoring, IMWG Publications

International Staging System for Multiple Myeloma

By imwgimf On May 20, 2005 · Add Comment · In Diagnosis, Staging & Monitoring, IMWG Publications

Purpose There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification. Patients and Methods Clinical �and �laboratory �data �were �gathered �on �10,750 �previously �untreated �symptomatic myeloma patients from 17 institutions, including sites in North America, Europe, and Asia. Potential prognostic factors were evaluated by univariate and multivariate techniques. Three modeling approaches were then explored to develop a staging system including two nontree and one tree survival assessment methodologies. Results Serum beta2-microglobulin (SB2M), serum albumin, platelet count, serum creatinine, and age emerged as powerful predictors of survival and were then used in the tree analysis approach. A combination […]

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Combining Fluorescent In Situ Hybridization (iFISH) data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group (IMWG) collaborative project

Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma

International Staging System for Multiple Myeloma

Categories

Search